Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

ytarabine (Ara-C) to cytarabine alone.

A second phase 3 study of clofarabine sponsored by the Eastern Cooperative Oncology Group is expected to begin enrolling patients next year. This study will compare single agent clofarabine to conventional induction chemotherapy in untreated AML patients age 60 and older who are considered suitable for conventional induction chemotherapy.

Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory ALL after at least two prior regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted.

Genzyme also is actively exploring additional therapeutic indications for Clolar, including in MDS.

Genzyme Hosts Investor Call Tomorrow Morning

Genzyme will host an investor call tomorrow morning, Tuesday, June 3 at 10 a.m. EST. The preliminary data from the CLASSIC-II pivotal study will be reviewed and there will be opportunity for investors to ask questions of Genzyme.

To participate in the call, please dial 1-888-982-7287 in the U.S. or 1-210-234-0251 outside of the U.S. The participant passcode is "Genzyme."

A replay of this call will be available by dialing 1-800-695-3397. This call will also be available live on the investor events section of http://www.genzyme.com. Replays of the call will be available until 10:59 p.m. on June 10, 2008.

About Clolar

Clolar has Orphan Drug designation for adult and pediatric ALL, and seven years of market exclusivity in the United States for relapsed/refractory pediatric ALL. The FDA also granted six months of extended market exclusivity to Clolar under the Best Pharmaceuticals for Children Act.

Clolar should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Pomerantz LLP is investigating claims on behalf of investors ... VTAE ).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... February 27, 2015, the Company announced that its partner ...
(Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... April 16, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc. will present ... agent BZL101, which is advancing to Phase 1/2,clinical ... American,Association of Cancer Research (AACR) being held at ... April 14 - 17, 2007. , Bionovo's poster ...
... Demonstrates Clinical Activity, a Novel Mechanism,of Action and ... HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ --,Achillion Pharmaceuticals, ... clinical antiviral activity of one of,Achillion's NS4A antagonists, ... infection at the 42nd Annual Meeting of the,European ...
Cached Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
(Date:3/1/2015)... York, NY (PRWEB) March 01, 2015 ... and seek insurance rates for term or universal policies ... of some of the best life insurance companies for ... through the system at http://quotespros.com/life-insurance.html . , The ... the search portal are tied to a number of ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Ticket Down is ... in Chicago at Soldier Field. Deadheads have been ... in January. , Grateful Dead was formed 50 years ago ... were together as one until the untimely death of Jerry ... combining different genres including blues, reggae, rock, bluegrass, folk, space ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 ERISAPros ... King and Carolyn Roddy to the professional staff of ... Compliance, graduated from The Ohio State University-Mortiz College of ... years of experience working with several Fortune 500 companies ... the area of corporate benefits. Her experiences range from ...
(Date:3/1/2015)... WA (PRWEB) February 28, 2015 CrossFit Attollo ... spring they are offering a special discount to new members. ... sign up for a three month contract will receive their ... month individually would cost members $440. The three month ... per month, and then the fourth month comes in at ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... , , SALEM, N.H., July ... President Tom Taylor to chair the trade organization,s Board of ... in developing and marketing disposable medical, diagnostic, and laboratory research ... recognized authority on practices and trends in the medical device ...
... fatal to chronic, researcher says , TUESDAY, July 14 ... mutated genes and gene processes that, together, contribute to ... tumor. , "There is not a single gene that ... Markus Bredel, co-author of two related papers in the ...
... , , URGES LEADERSHIP ON LUNG ... Today Lung Cancer Alliance praised President Obama,s nomination of Dr. Regina ... whose mother died of lung cancer, to change public awareness and public ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) , ...
... , , ATLANTA, July 14 ... and Medical Spa has earned the country,s first LEED certification for ... the nation,s healthiest and most energy efficient medical spa and venous ... Green Building Council (USGBC), the nation,s leading evaluator of environmentally sustainable ...
... , ... that the deaths could have been prevented, mourns highly experienced New York personal injury attorney, ... New York, ... on June 29, 2009 in a gruesome personal injury accident at a privately ...
... , SAN FRANCISCO, July 14 Burrill ... on its recently-completed divestment of three investigational compounds for dermatological ... agreement were not disclosed. , , ... inhibitor currently in Phase 2 development for the treatment of ...
Cached Medicine News:Health News:Roush Life Sciences' Taylor to Chair MassMEDIC 2Health News:Gene Connections Key to Brain Tumor Growth 2Health News:Gene Connections Key to Brain Tumor Growth 3Health News:LCA Congratulates Nominee For Surgeon General 2Health News:OH2 Medical Spa Achieves the First U.S. LEED(R) Certification for a Medical Commercial Interior 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 3Health News:Burrill Merchant Banking Advises Pfizer Inc. on Dermatology Portfolio Divestment 2
... full monochromatic and chromatic correction for the ... rich-contrast, completely flat images for observation and ... transmission of wavelengths up to the near ... of glass types of low autofluorescence makes ...
Inquire...
This is the most versatile family of objectives. One and the same set of objectives can be used for all common contrasting methods: Brightfield, darkfield, phase contrast, DIC, epi-fluorescence, and ...
... objectives have been completely redesigned by Nikon ... using a modulator inside the objective. That ... entire magnification range from 10x to 40x.,Apodized ... reduce halos in the image by reducing ...
Medicine Products: